CoChat

The DOI matches its Crossref record; 104 of the 106 references it cites were found in a registry or an index; 53 of the 139 sources its claims cite were checked for support.

Implication of Trimethylamine N-Oxide (TMAO) in Disease: Potential Biomarker or New Therapeutic Target

Open access
Janeiro, Manuel, Ramírez, María, Milagro, Fermin, Martínez, J., Solas, Maite · 2018 · Nutrients

Abstract

Trimethylamine N-oxide (TMAO) is a molecule generated from choline, betaine, and carnitine via gut microbial metabolism. The plasma level of TMAO is determined by several factors including diet, gut microbial flora, drug administration and liver flavin monooxygenase activity. In humans, recent clinical studies evidence a positive correlation between elevated plasma levels of TMAO and an increased risk for major adverse cardiovascular events. A direct correlation between increased TMAO levels and neurological disorders has been also hypothesized. Several therapeutic strategies are being explored to reduce TMAO levels, including use of oral broad spectrum antibiotics, promoting the growth of bacteria that use TMAO as substrate and the development of target-specific molecules. Despite the accumulating evidence, it is questioned whether TMAO is the mediator of a bystander in the disease process. Thus, it is important to undertake studies to establish the role of TMAO in human health and disease. In this article, we reviewed dietary sources and metabolic pathways of TMAO, as well as screened the studies suggesting possible involvement of TMAO in the etiology of cardiovascular and neurological disorders, underlying the importance of TMAO mediating inflammatory processes. Finally, the potential utility of TMAO as therapeutic target is also analyzed.

Overview

CoChat Summary

TL;DR

TMAO is a gut-microbiota-derived metabolite of dietary choline, betaine, and carnitine that is oxidized hepatically by FMO3 and has been positively associated with cardiovascular events, neurological disorders, and inflammation. This narrative review concludes that TMAO may be a biomarker or therapeutic target, but causality remains unresolved because it may instead be a bystander.

Key findings

  • TMAO is generated from choline, betaine, L-carnitine, γ-butyrobetaine, and ergothioneine via gut microbial TMA, then oxidized mainly by hepatic FMO3; FMO1 has tenfold lower specific activity in liver. Nearly 95% of TMA is oxidized and excreted in urine in a 3:95 TMA:TMAO ratio within 24 h, with only 4% excreted in feces and less than 1% in breath.
  • Elevated plasma TMAO is positively correlated with increased risk for major adverse cardiovascular events, but the association is inconsistent: bariatric surgery raises TMAO despite reducing CVD risk, fish/seafood are rich in TMAO yet not linked to increased CVD risk, and FMO3 may influence atherosclerosis independently of TMAO.
  • TMAO has been linked to neurological disorders in both harmful and protective directions: it can stabilize/modify amyloid beta aggregation and disrupt the blood-brain barrier, but as an osmolyte/chemical chaperone it can promote tau-tubulin assembly, inhibit PrPC-to-PrPSc conversion, reduce ataxin-3 aggregation, and favor compact α-synuclein forms.
  • Inflammation is proposed as an underlying mechanism: TMAO is associated with TNF-α, IL-6, and C-reactive protein, and activates NLRP3 inflammasome via SIRT3-SOD2-mitochondrial ROS or ROS-TXNIP pathways; therapeutic strategies include antibiotics, pre/probiotics, methanogenic bacteria, DMB, meldonium, herbal products, resveratrol, and enalapril, though antibiotics suppress TMAO only until about one month after withdrawal.

Methods

  • Narrative review of dietary sources and metabolic pathways of TMAO, plus screening of studies suggesting involvement in cardiovascular and neurological disorders, inflammation, and therapeutic strategies.
  • Evidence base consists of cited human clinical/observational studies, animal models, and cell experiments; no new primary data are reported.
  • Main analysis is qualitative synthesis, with referenced tables (Tables 1–5) organizing diet, CVD, neurological, inflammation, and therapeutic findings; no systematic search strategy or meta-analysis is described.

Limitations

  • The paper states that the exact mechanism underlying the correlation between high plasma TMAO and atherosclerosis is still unknown, and it is questioned whether TMAO is a mediator or a bystander in disease.
  • The paper states that human dietary TMAO metabolism is poorly understood and that the amount of TMA excreted in feces has not been carefully quantified.
  • Evident from the text: this is a narrative review without systematic search or quantitative synthesis, and many conclusions rely on animal/cell studies or mixed human observational findings, so causality cannot be established.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.3390/nu10101398

Cites

104 of 104 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1 Pathways for trimethylamine N-oxide (TMAO) formation. Trimethylamine (TMA) is formed in the intestinal lumen when gut microbiota metabolize carnitine, choline, and choline-containing compounds in the diet. TMA can be absorbed from the intestine. This absorbed TMA is delivered to the liver where flavin-dependent monooxygenase (FMO) isoforms 1 and 3 convert it to TMAO. DMA: dimethylamine; HCHO: formaldhyde; TMADH: trimethylamine dehydrogenase; CoA: coenzyme A.
Figure 1 Pathways for trimethylamine N-oxide (TMAO) formation. Trimethylamine (TMA) is formed in the intestinal lumen when gut microbiota metabolize carnitine, choline, and choline-containing compounds in the diet. TMA can be absorbed from the intestine. This absorbed TMA is delivered to the liver where flavin-dependent monooxygenase (FMO) isoforms 1 and 3 convert it to TMAO. DMA: dimethylamine; HCHO: formaldhyde; TMADH: trimethylamine dehydrogenase; CoA: coenzyme A.CC BY · PubMed Central

Verification

Claims the paper makes

24 Valid · 2 Not valid · 67 Not checked · 7 Own results and interpretations

41 more claims · 13 with their cited sources checked

Create a free account to see all 100 claims and to verify the 86 references still open.

See all claims — free account
  • It may state two separate claims as one. 48
  • Probably not a substantial claim. 7

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 106 references

Cited by

See all 631

Metadata

Authors
Janeiro, M., Ramírez, M., Milagro, F., Martínez, J., & Solas, M.
Affiliations
  • Navarre Institute of Health Research (ES)
  • Instituto de Salud Carlos III (ES)
Corresponding author
Solas, Maite
Venue
Nutrients
Publisher
MDPI AG
Published
2018-10-01
Volume
10
Issue
10
Pages
1398
ISSN
2072-6643 (ISSN-L)
OpenAlex
W2892844483
Cited by
631
References
106
Citations by year
2026: 46 · 2025: 79 · 2024: 100 · 2023: 90 · 2022: 112 · 2021: 102 · 2020: 71 · 2019: 31
FWCI
4.99
Type
journal article
Language
en
Open access
Locations
  • Nutrients (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, other-oa)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Deposito Adademico Digital Universidad De Navarra (University of Navarra) (submittedVersion, other-oa)
  • Deposito Adademico Digital Universidad De Navarra (University of Navarra) (submittedVersion, cc-by)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • Gobierno de Navarra (PI035)
  • Instituto de Salud Carlos III
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Polyamine Metabolism and Applications
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Metabolism and Genetic Disorders
Keywords
trimethylamine N-oxide, gut microbiota, cardiovascular disease, neurological disorders, biomarkers, therapeutic target, flavin-containing monooxygenase, choline metabolism, food sources, inflammation, broad-spectrum antibiotics, gut-brain axis
MeSH terms
Cardiovascular Diseases, Humans, Methylamines, Nervous System Diseases, Biomarkers, Inflammation Mediators, Metabolic Networks and Pathways, Molecular Targeted Therapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-07, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-07 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Implication of Trimethylamine N-Oxide (TMAO) in Disease: Potential Biomarker or New Therapeutic Target. https://app.cochat.ai/papers/10.3390/nu10101398
The paper
Janeiro, M., Ramírez, M., Milagro, F., Martínez, J., & Solas, M. (2018). Implication of Trimethylamine N-Oxide (TMAO) in Disease: Potential Biomarker or New Therapeutic Target. Nutrients. https://doi.org/10.3390/nu10101398

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.